Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients  E.B. Wilms, D.J. Touw, H.G.M. Heijerman 

Slides:



Advertisements
Similar presentations
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Advertisements

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice 
The prevalence of “risky behaviour” in adults with cystic fibrosis
P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham 
E. M. Westerman, A. H. De Boer, P. P. H. Le Brun, D. J. Touw, A. C
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
The pharmacokinetics and toxicity of morning vs
H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 
Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis?  Darren Shepherd, Yvonne Belessis,
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands  R.W. Brimicombe, L. Dijkshoorn, T.J.K.
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis  Marco Zampoli, Komala Pillay, Henri Carrara,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Cirrhosis and other liver disease in cystic fibrosis
Controlled clinical trials in cystic fibrosis — are we doing better?
Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time  Rosemary Ball, Kevin W. Southern, Pamela.
Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar 
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial  S.K. Kabra, R. Pawaiya, Rakesh Lodha,
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis  Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,
Amyloidosis in cystic fibrosis: A case series
Spontaneous coronary artery dissection associated with coughing
A.H. Gifford  Journal of Cystic Fibrosis 
Demographics of glucose metabolism in cystic fibrosis
Inhalation solutions — Which ones may be mixed
Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C
Elisabeth P. Dellon, Elaine Chen, Jessica Goggin, Karen Homa, Bruce C
Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India  Shivaram S. Shastri, Madhulika Kabra, Sushil.
Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration  Drucy Borowitz, Daniel Gelfond, Karen.
Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis 
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?
Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi 
Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance  P. Goncalves-Vidigal,
Nasal polyposis in lung transplant recipients with cystic fibrosis
Antine E. Stenbit, Wendy M. Bullington, Julie L. Heh, Patrick A. Flume 
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal 
Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS  Dorota Sands, Ewa Sapiejka, Grzegorz.
Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids  Francis J. Gilchrist, A.
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
H. White, A.M. Morton, S.P. Conway, D.G. Peckham 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case– control study  Maarten Verregghen, Harry G. Heijerman, Monique.
C. L. Vreede, M. C. Berkhout, A. J. Sprij, W. J. Fokkens, H. G. M
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study  E.M. Westerman, P.P.H.
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Beta-lactam allergy in adults with cystic fibrosis
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Anne K. Swisher, Kathryn Moffett, Linda Baer 
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population  Elaine.
Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis  D.J. Touw, A.J. Knox,
Cystic fibrosis and pregnancy in the modern era: A case control study
R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P
Safety assessment of inhaled xylitol in subjects with cystic fibrosis
Presentation transcript:

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients  E.B. Wilms, D.J. Touw, H.G.M. Heijerman  Journal of Cystic Fibrosis  Volume 7, Issue 1, Pages 79-84 (January 2008) DOI: 10.1016/j.jcf.2007.05.005 Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Individual sputum concentrations of azithromycin (AZM) during dose regimen 1 (500 mg once-daily; day 1) and dose regimen 2 (1000 mg once-weekly; after 1, 2 and 3 months). AZM concentration was determined in spontaneously produced sputum collected on the day before administration of the weekly dose of AZM. Journal of Cystic Fibrosis 2008 7, 79-84DOI: (10.1016/j.jcf.2007.05.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions